PhD candidate at UW Genome Sciences | using proteomics to study how novel proteins function
Catherine Sniezek
Rather than listening to the Daily every morning, I’ve been plugging away through this book, which is more a book on the writing process than it is about notes.
Am I more productive yet? Who knows but at least I’m slightly less Sad
open.spotify.com/show/0nj0WAO...
Excited to share our latest preprint from us at the Schweppe Lab detailing detergent impacts to thermal stability with consequences for thermal profiling: DDM behaves quite differently from NP-40 when used as a component of a melting buffer!
@dschweppe.bsky.social
www.biorxiv.org/content/10.6...
www.biorxiv.org
Catherine Sniezek
Catherine Sniezek
(BioRxiv All) Serum proteomics reveals distinct phenotypic signatures to IL-6 blockade between two immunotherapies: A recent clinical study tested the effects of two different monoclonal antibodies (mAbs) (siltuximab, anti-IL6; tocilizumab, anti-IL6R) on the fate and function… #BioRxiv #MassSpecRSS
More exciting work from the lab!
Along with @maccoss.bsky.social (@uwgenome.bsky.social) and Gary Churchill (@jax.org), Dr. Katarina Vlajic's tour de force multi-omics profiling uncovered molecular signatures of healthy splenic aging!
www.biorxiv.org/content/10.6...
A recent clinical study tested the effects of two different monoclonal antibodies (mAbs) (siltuximab, anti-IL6; tocilizumab, anti-IL6R) on the fate and function of T-cells in people with type 1 diabetes. While both mAbs affect the response of T-cells to stimulation, they have very different, sometimes opposing mechanisms. Here, we use mass-spectrometry based proteomics to analyze longitudinal serum samples (baseline and two weeks post-treatment) from 20 clinical trial participants to examine the effects of siltuximab and tocilizumab on extracellular vesicles. To accomplish this, serum samples were enriched for extracellular vesicles with Mag-Net and analyzed by LC-MS/MS to identify significantly differentially abundant protein groups and pathways. Proteome analysis confirmed highly reproducible measurements across multiple draw dates. In total, we quantified 3300 protein groups of which 46 protein groups had significantly altered abundance after mAb treatment. Tocilizumab altered pathways associated with proteostasis (neddylation) and pre-notch transcription and translation. Siltuximab altered FCGR activation pathway members. In addition, quantitation of the monoclonal antibody therapies themselves enabled the measurement of the correlation between drug amounts and impacted proteins. Taken together, this work demonstrates the utility of the Mag-Net method to evaluate the impacts of therapeutic interventions on serum extracellular vesicles.
